[go: up one dir, main page]

PE20020957A1 - Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas - Google Patents

Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas

Info

Publication number
PE20020957A1
PE20020957A1 PE2002000110A PE2002000110A PE20020957A1 PE 20020957 A1 PE20020957 A1 PE 20020957A1 PE 2002000110 A PE2002000110 A PE 2002000110A PE 2002000110 A PE2002000110 A PE 2002000110A PE 20020957 A1 PE20020957 A1 PE 20020957A1
Authority
PE
Peru
Prior art keywords
alkyl
inhibitors based
pyrimidinones
pyrimidin
prop
Prior art date
Application number
PE2002000110A
Other languages
English (en)
Inventor
William Glen Harter
Jie Jack Li
Wen-Song Yue
Kevon Ray Shuler
Daniel Fred Ortwine
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20020957A1 publication Critical patent/PE20020957A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE REFIERE A PIRIMIDINONAS BICICLICAS DE FORMULA I DONDE W JUNTO CON LOS ATOMOS DE CARBONO A LOS QUE ESTAN UNIDOS FORMAN EL GRUPO a, b, ENTRE OTROS. A ES -C-, -S-; B ES O, NR5; A Y B JUNTOS FORMAN UN -C=C-; X ES O, S, SO, SO2, NR5; Y ES O, S; R1, R4 Y R5 SON H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; R2 Y R3 SON H, ALQUILO C1-C6, ALQUENILO C2-C6,ENTRE OTROS; R2 ES HALO; n ES 0-5; R4 Y R5 JUNTO A N COMPLETAN UN ANILLO CE 3 A 8 MIEMBROS. SON COMPUESTOS PREFERIDOS ACIDO 4-{6-[3-(4-METOXI-FENIL)-PROP-1-INIL]-1-METIL-2,4-DIOXO-1,4-DIHIDRO-2H-TIENO[2,3-d]PIRIMIDIN-3-ILMETIL}-BENZOICO, 3-(4-METANOSULFONIL-BENCIL)-6-[3-(4-METOXI-FENIL)-PROP-1-INIL]-1-METIL-1H-TIENO[2,3-d]PIRIMIDIN-2,4-DIONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE METALOPROTEINASAS Y SON UTILES PARA EL TRATAMIENTO DE ARTRITIS, OSTEOARTRITIS
PE2002000110A 2001-02-14 2002-02-12 Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas PE20020957A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26875601P 2001-02-14 2001-02-14

Publications (1)

Publication Number Publication Date
PE20020957A1 true PE20020957A1 (es) 2002-11-08

Family

ID=23024328

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000110A PE20020957A1 (es) 2001-02-14 2002-02-12 Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas

Country Status (15)

Country Link
US (1) US20030004172A1 (es)
EP (1) EP1370562A1 (es)
JP (1) JP2004518732A (es)
BR (1) BR0207216A (es)
CA (1) CA2433778A1 (es)
DO (1) DOP2002000337A (es)
GT (1) GT200200017A (es)
HN (1) HN2002000029A (es)
MX (1) MXPA03004926A (es)
PA (1) PA8538301A1 (es)
PE (1) PE20020957A1 (es)
SV (1) SV2003000882A (es)
TN (1) TNSN02009A1 (es)
UY (1) UY27159A1 (es)
WO (1) WO2002064598A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
EA007484B1 (ru) * 2001-06-11 2006-10-27 Вирокем Фарма Инк. Соединения и способы лечения или предупреждения инфекций flavivirus
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
MXPA04002537A (es) 2001-10-12 2004-05-31 Warner Lambert Co Alquinos como inhibidores de metaloproteinasa de matriz.
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
CA2495432A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
CA2492391A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
BR0312727A (pt) * 2002-07-17 2005-04-19 Warner Lambert Co Combinação de um inibidor alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
WO2004014869A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
CA2494014A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
CA2492019A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Isoquinoline derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
DE60313350T2 (de) 2002-08-13 2008-01-03 Warner-Lambert Company Llc Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014908A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003250465A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
MXPA05001786A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
MXPA05007990A (es) 2003-01-29 2005-09-20 Takeda Pharmaceutical Compuestos de tienopirimidina y uso de los mismos.
JP2008094846A (ja) * 2003-01-29 2008-04-24 Takeda Chem Ind Ltd チエノピリミジン化合物およびその用途
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US7570259B2 (en) 2004-06-01 2009-08-04 Intel Corporation System to manage display power consumption
ES2310861T3 (es) 2004-12-08 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos como inhibidores del factor viia.
WO2007103776A2 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
ES2399928T3 (es) * 2006-08-23 2013-04-04 Neurogen Corporation Análogos de 2-fenoxipirimidinona
WO2008070529A2 (en) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
EP1939197A1 (en) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
WO2008138126A1 (en) * 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
AR077898A1 (es) 2009-08-26 2011-09-28 Nycomed Gmbh Metilpirrolopirimidincarboxamidas
UA123760C2 (uk) * 2011-11-11 2021-06-02 Гіліад Аполло, Ллс Сполука (варіанти) та композиція, що містить сполуку
EA201600318A1 (ru) * 2013-10-07 2016-09-30 Байер Фарма Акциенгезельшафт Циклические тиеноурацилкарбоксамиды и их применение
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
KR20180082556A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 피라졸 acc 억제제 및 그의 용도
EP3379933B1 (en) 2015-11-25 2023-02-15 Gilead Apollo, LLC Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
ES2939977T3 (es) 2015-11-25 2023-04-28 Gilead Apollo Llc Inhibidores de triazol ACC y usos de los mismos
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
PE20190474A1 (es) 2016-09-23 2019-04-04 Bayer Ag Tienouracilos n3-ciclicamente sustituidos y uso de los mismos
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
CN110183464B (zh) * 2019-05-31 2021-08-31 淮阴工学院 一种抗癌化合物艾斯替尼及其合成方法和应用
KR102649886B1 (ko) * 2021-07-21 2024-03-22 충남대학교산학협력단 신규한 피리미딘-4-온 화합물 및 이를 포함하는 항암제 조성물
EP4568971A1 (en) * 2022-08-09 2025-06-18 Vanderbilt University Antagonists of 5-hydroxytryptamine receptor subtype 2b

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155665A (en) 1961-04-26 1964-11-03 Searle & Co 4, 6-dialkyl-5, 7-diketothiazolo [4, 5-d] pyrimidine-2-carboxylic acid and derivatives thereof
US3277093A (en) 1965-08-02 1966-10-04 Searle & Co (optionally-2-substituted) 4-halophenyl-5, 7-diketo-6-alkylthiazolo[4, 5-d]pyrimidines
GB8601371D0 (en) 1986-01-21 1986-02-26 Beecham Group Plc Compounds
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US6048863A (en) * 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
AU699354B2 (en) * 1994-11-08 1998-12-03 Takeda Chemical Industries Ltd. Thienopyridine or thienopyrimidine derivatives useful as anti-inflammatory agents or in the treatment of osteoporosis
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
WO1997046560A1 (en) * 1996-06-06 1997-12-11 Otsuka Pharmaceutical Factory, Inc. Amide derivatives
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6166019A (en) * 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
DK1107973T3 (da) * 1998-08-28 2004-02-23 Astrazeneca Ab Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
DE19940494C1 (de) * 1999-08-26 2001-02-15 Ibfb Gmbh Privates Inst Fuer B Mehrcyclische Pyrimidin-2,4(1H,3H)-dione mit funktionalisierten Alkylresten in 1- und/oder 3-Position, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US20050004111A1 (en) * 2003-01-03 2005-01-06 Aventis Pharma Deutschland Gmbh Selective MMP-13 inhibitors

Also Published As

Publication number Publication date
US20030004172A1 (en) 2003-01-02
GT200200017A (es) 2002-11-15
MXPA03004926A (es) 2005-02-14
EP1370562A1 (en) 2003-12-17
HN2002000029A (es) 2003-02-14
CA2433778A1 (en) 2002-08-22
JP2004518732A (ja) 2004-06-24
UY27159A1 (es) 2002-09-30
BR0207216A (pt) 2004-03-09
TNSN02009A1 (fr) 2005-12-23
SV2003000882A (es) 2003-01-13
WO2002064598A1 (en) 2002-08-22
DOP2002000337A (es) 2002-08-15
PA8538301A1 (es) 2002-09-17

Similar Documents

Publication Publication Date Title
PE20020957A1 (es) Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas
PE20000639A1 (es) COMPUESTOS DE PIRROLO[2,3-d]PIRIMIDINA
PE20020381A1 (es) COMPUESTOS DE PIRROLO[2,3-d]PIRIMIDINA COMO INHIBIDORES DE LA PROTEINA QUINASA
PE20020961A1 (es) Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
AR016499A1 (es) Compuestos de pirrolo[2,3-d]pirimidina, composiciones y procesos para su uso en medicina.
PE20020254A1 (es) Derivados de piridina
MX9303441A (es) Procedimiento para la preparacion de acido clavulanico.
BRPI0507734A (pt) composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
BRPI0507746A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
ES2721268T3 (es) Compuestos de pirazolo[1,5-a]pirimidina-5,7-diamina como inhibidores de CDK y su uso terapéutico
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
PE20011228A1 (es) Derivados de piridopirimidina o iminopirimidina utiles para el tratamiento de enfermedades neurodegenerativas
PE20020874A1 (es) Pirimidinas inhibidoras de metaloproteinasas de matriz
PT1278750E (pt) Derivados de imidazopirimidina e derivados de triazolopirimidina
PA8507301A1 (es) COMPUESTOS DE PIRROLO (2,3-d) PIRIMIDINA
PE20011164A1 (es) Derivados de eteres de pirazol como agentes antiinflamatorios / analgesicos
PE20020305A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA
PT911333E (pt) Derivados de pirazolo¬4,3-d|pirimidina e composicoes farmaceuticas que os contenham
CO6190512A2 (es) Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso
PE20020206A1 (es) Metodos y composiciones que comprenden nucleosidos para tratar el virus de la hepatitis c
MY134081A (en) N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad.
DK0869946T3 (da) Phenylimidazolidiner og deres anvendelse som anti-androgent middel
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
PE20050473A1 (es) Nuevos derivados de pirimidin-2-amina
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario

Legal Events

Date Code Title Description
FD Application declared void or lapsed